Treatment
Trastuzumab clinical trials
We’re tracking 234 recruiting studies that include Trastuzumab, each written for real people, not researchers, below.
Recruiting studies
- NCT07281001Recruiting
Trastuzumab deruxtecan study for breast cancer patients
This study looks at how well the drug trastuzumab deruxtecan works in women with breast cancer that has spread. It is for patients who have already taken this drug.
MoscowAges 18–80 - NCT07741448RecruitingPhase 2
Chemo and targeted drug before surgery for HER2-positive upper tract cancer
This trial tests a combination of chemotherapy (gemcitabine) and a targeted drug (Trastuzumab Rezetecan) before surgery to remove the kidney and ureter. It may help shrink the tumor and improve outcomes for people with HER2-positive upper tract urothelial cancer.
Huanggang, HubeiAges 18–75 - NCT06832202RecruitingPhase 2
HLX22 plus Enhertu for HR+, HER2-low breast cancer
This trial tests a new drug, HLX22, combined with Enhertu (trastuzumab deruxtecan) for people with advanced breast cancer that is hormone receptor positive and HER2-low. The goal is to see if the combination works better than Enhertu alone.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06846437RecruitingPhase 3
New drug JSKN003 vs. Kadcyla for HER2-positive advanced breast cancer
This trial compares a new targeted therapy (JSKN003) against Kadcyla (T-DM1) for people with HER2-positive breast cancer that has advanced or spread. Both drugs work by attaching a chemotherapy directly to HER2-positive cancer cells, and the study aims to see if the new drug works better or has fewer side effects.
ShanghaiAges 18 years+ - NCT07635342RecruitingPhase 2
Pyrotinib plus trastuzumab and chemotherapy for HER2-positive early breast cancer
This trial tests a combination of three drugs—pyrotinib, trastuzumab, and chemotherapy—to treat HER2-positive breast cancer that has not been treated before. HER2 is a protein found on some cancer cells; blocking it may help stop the cancer from growing.
Shijiazhuang, HebeiAges 18–65 - NCT07263425RecruitingPhase 2
Study of thiotepa and trastuzumab for breast cancer that spread to the lining of the brain and spinal cord
This trial tests a combination of two drugs given through a special port in the head to treat HER2-positive breast cancer that has spread to the layer covering the brain and spinal cord (leptomeningeal metastasis). It aims to see if this treatment is safe and effective.
Nanjing, JiangsuAges 18–75 - NCT06876714RecruitingPhase 3
Shorter vs Longer HER2 Therapy for Breast Cancer with Complete Response
This trial compares 6 months versus 12 months of HER2-targeted therapy for people with HER2+ breast cancer who had a complete response after chemo and trastuzumab. The goal is to see if a shorter treatment is just as effective.
Phoenix, ArizonaAges 18 years+ - NCT07413939RecruitingPhase 2/Phase 3
Study of RO7771950 vs tucatinib for HER2-positive breast cancer
This trial tests a new drug, RO7771950, against another drug called tucatinib. Both are given with standard chemotherapy to see which works better for advanced breast cancer that is HER2-positive. People with brain metastases may join.
Germantown, TennesseeAges 18 years+ - NCT07518173RecruitingPhase 3
BL-M07D1 plus Pertuzumab for HER2-positive breast cancer
This trial tests whether a new cancer drug called BL-M07D1, combined with pertuzumab, works better or as well as standard chemotherapy for advanced HER2-positive breast cancer that has spread or come back. HER2-positive means the cancer cells have high levels of a protein called HER2, which makes them grow faster.
Guangzhou, GuangdongAges 18–75 - NCT04616560RecruitingPhase 1/Phase 2
New drug for recurrent Wilms tumor, osteosarcoma, and DSRCT
This trial tests a targeted drug called trastuzumab deruxtecan for children and young adults with certain cancers that have come back or not responded to treatment. It may help if your tumor has not responded to standard therapies.
Birmingham, AlabamaAges 12–39 - NCT07022483RecruitingPhase 3
New drug vs standard chemo for HER2-positive endometrial cancer
This trial compares a new targeted medicine (trastuzumab deruxtecan) against standard chemotherapy for women with a certain type of advanced endometrial cancer that has high levels of HER2 protein. It's for people whose cancer is newly diagnosed and has spread to nearby tissues but not to distant organs.
Fort Lauderdale, FloridaAges 18 years+ - NCT05372614RecruitingPhase 1
Testing trastuzumab deruxtecan and neratinib for HER2-positive cancers
This trial tests a combination of two targeted drugs, trastuzumab deruxtecan (Enhertu) and neratinib, for people with solid tumors that have a HER2 gene change. The goal is to see if the combination is safe and works well for cancers that have not responded to at least one prior treatment.
Duarte, CaliforniaAges 18 years+ - NCT05253651RecruitingPhase 3
Tucatinib plus trastuzumab with chemo for HER2+ metastatic colon cancer
This trial tests whether adding tucatinib and trastuzumab to standard chemotherapy works better than standard treatment alone for people with HER2-positive metastatic colon or rectal cancer. It aims to improve how long people live and how well tumors respond as first treatment for advanced disease.
Glendale, ArizonaAges 18 years+ - NCT07716189RecruitingPhase 3
Ear Acupuncture plus Dexamethasone for Nausea from Trastuzumab Deruxtecan
This trial tests if adding ear acupuncture to a standard anti-nausea medicine (dexamethasone) works better for nausea and vomiting caused by the breast cancer drug trastuzumab deruxtecan. The goal is to help you feel better during treatment.
HangzhouAges 18–85 - NCT06899126RecruitingPhase 3
Study of a drug combo for first-line HER2-positive lung cancer
This trial tests a new combination of drugs (trastuzumab deruxtecan, pembrolizumab, and chemotherapy) as a first treatment for people with advanced non-small cell lung cancer that has high levels of the HER2 protein. The goal is to see if this combination works better than current options.
Anchorage, AlaskaAges 18 years+ - NCT07704177RecruitingPhase 2
A study of trastuzumab rezetecan plus two other drugs for advanced bile duct cancer
This trial tests a combination of three drugs (trastuzumab rezetecan, adebrelimab, and lenvatinib) for people with advanced bile duct or gallbladder cancer that has HER2 protein on its cells. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18–80 - NCT04341181RecruitingPhase 2
Targeted cancer treatment chosen by tumor genetic test results
This Phase 2 trial matches people with advanced cancer to a targeted treatment based on a genetic (DNA) or protein (IHC) test from their tumor. It’s for cancers that are no longer responding to standard treatment or where no standard option is available.
Aalborg, AalborgAges 18 years+ - NCT04379596RecruitingPhase 2
Testing T-DXd combinations for HER2 stomach or esophagus cancer
This Phase 2 study tests how safe and effective T-DXd (an anti-cancer medicine) is in combination for people with advanced stomach/GEJ/esophagus cancer that is HER2-positive or HER2-low. It may help people whose cancer has spread or cannot be removed, depending on their prior treatments and test results.
Santa Monica, CaliforniaAges 18–130 - NCT04553770RecruitingPhase 2
Trastuzumab deruxtecan with or without anastrozole for early breast cancer
This Phase 2 study tests whether trastuzumab deruxtecan alone or combined with anastrozole can control early-stage breast cancer that is HER2-low and hormone-receptor positive. It aims to improve outcomes after initial surgical treatment by targeting cancer cells that may have low levels of HER2.
Fullerton, CaliforniaAges 18 years+ - NCT04680442RecruitingPhase 2
Keeping HER2 therapy when your heart function is weaker
This trial studies whether it’s safe to continue HER2-targeted breast cancer treatment (like trastuzumab, pertuzumab, or T-DM1) even when heart function (left ventricle) is reduced. It may help people avoid stopping a helpful cancer medicine because of heart concerns.
Porto Alegre, Rio Grande do SulAges Any age - NCT04886531RecruitingPhase 2
Pre-surgery neratinib plus hormone therapy with trastuzumab
This study tests whether a pre-surgery treatment plan that adds neratinib to hormone therapy and trastuzumab can shrink HER2-positive, ER-positive breast cancer before surgery. It may help patients by improving how much cancer is eliminated at the time of surgery.
Chicago, IllinoisAges 18 years+ - NCT07137416RecruitingPhase 1
Testing a new combination of cancer drugs for HER2-positive tumors and breast cancer
This trial tests the safety of combining two drugs, CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd), in people with HER2-positive solid tumors or certain types of breast cancer. If you have advanced cancer that hasn't responded to other treatments, this study may be an option.
Boston, MassachusettsAges 18 years+ - NCT05187182RecruitingPhase 1
Testing a new cancer drug with FOLFOX and immune therapy
This Phase 1 study tests CA-4948 given with standard chemotherapy (FOLFOX) and an immune therapy (an immune checkpoint inhibitor, similar to PD-1). It’s for people with advanced stomach or esophageal cancer that can’t be removed by surgery, to see how well the treatment works and whether it’s safe.
St Louis, MissouriAges 18 years+ - NCT05188313RecruitingPhase 3
HER2 medicines before surgery for resectable esophageal cancer
This trial tests two targeted medicines, trastuzumab and pertuzumab (HER2-blocking drugs), given before surgery for HER2-positive esophageal or stomach-esophagus junction cancer. The goal is to shrink the tumor and improve how well surgery works and outcomes after treatment.
AmsterdamAges 18 years+
Common questions
- Are there clinical trials studying Trastuzumab?
- Yes. Clin2 currently lists 234 recruiting studies that include Trastuzumab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Trastuzumab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Trastuzumab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Trastuzumab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.